Market News & Trends
Curia Recognized on India Pharma Outlook’s 2023 List of Top 10 CDMO Companies in India
Curia recently announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook. The full list can be…
Rumi Scientific Announces Partnership With X-Chem for Development of Lead Candidate in Huntington’s Disease
Rumi Scientific recently announced it has entered into a partnership with X-Chem through which X-Chem will develop a lead candidate BRD9 inhibitor for the treatment…
Colorcon Unveils Corelease - A Unified Brand for Novel Controlled-Release Formulated Systems
Ready formulated systems approach simplifies the development and manufacturing for controlled release…..
Ocean Biomedical Announces Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody
Ocean Biomedical, Inc. recently announced its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of….
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab With New US Patent Issuance
Checkpoint Therapeutics, Inc. recently announced the US Patent and Trademark Office (USPTO) has issued a new patent (US Patent No. 11,834,505) covering a method of…
Oxford Biomedica Signs Agreement to Acquire ABL Europe, Consolidating Position as a Global Pure-Play CDMO
Oxford Biomedica plc recently announced it has entered into a sale and purchase agreement with TSGH SAS, a subsidiary of Institut Mérieux SA, for the acquisition of….
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
GT Biopharma, Inc. recently announced the submission of an Investigational New Drug (IND) application with the US FDA for the development of GTB-3650, a 2nd…
Absci Announces Collaboration With AstraZeneca to Advance AI-Driven Oncology Candidate
Absci Corporation recently announced a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation platform…
AbbVie to Acquire ImmunoGen, Including its Flagship Cancer Therapy, Expanding Solid Tumor Portfolio
AbbVie Inc. and ImmunoGen, Inc. recently announced a definitive agreement under which AbbVie will acquire ImmunoGen and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class….
Samsung Bioepis Secures US License Date for SB17, a Proposed Biosimilar to Stelara
Samsung Bioepis Co., Ltd. has recently signed a settlement and license agreement with Johnson & Johnson settling all pending US patent litigation between the two…
Orchard Therapeutics Receives US FDA Fast Track Designation for OTL-203 in MPS-IH
Orchard Therapeutics recently announced the US FDA has granted Fast Track designation to OTL-203, an investigational hematopoietic stem cell gene (HSC) therapy being developed for…
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
Tiziana Life Sciences Ltd. recently announced it has successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham…
Hovione Expands Nasal Drug Delivery Capabilities With Development of Nasal Powder Delivery Device Technology in Collaboration With IDC
Hovione and Industrial Design Consultancy (IDC) have entered into a joint development of an innovative nasal powder delivery device technology supporting local, systemic, and nose-to-brain drug delivery….
Ardena's New Aseptic Fill-Finish Plant in Ghent Receives GMP License
Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has been granted a Good Manufacturing Practice (GMP) license by the….
BiomX Announces Positive Topline Results From Part 2 of the Phase 1b/2a Trial Evaluating Treatment for Chronic Pulmonary Infections in Patients With Cystic Fibrosis
BiomX Inc. recently announced positive safety and efficacy results from Part 2 of the Phase 1b/2a trial evaluating the company’s novel phage cocktail, BX004, for…
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung
Oxford BioTherapeutics recently announced the US FDA has granted Fast Track designation to BI 764532 for the potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of….
Dyadic Announces Top-Line Results From its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic International, Inc. recently announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100. This marks the…
Lumen Bioscience Announces $5.5-Million Funding to Support New Research Program for Mucosal Vaccine Platform Technology
Lumen Bioscience recently announced $5.5 million in new funding from the US Department of Defense, operating through the Medical CBRN Defense Consortium (MCDC), to develop…
Roivant Announces Positive IMVT-1402 Initial 600-mg MAD Results That Confirm Best-in-Class Potential
Immunovant, Inc. recently announced initial data from 600-mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults. The results show that…
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration With Bristol Myers Squibb
Global licensing and research collaboration to focus on discovery, development and commercialization of up to five cardiovascular targets leveraging Avidity’s proprietary AOC platform technology….
